Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Radiopharmaceuticals and Molecular Imaging

Bart Cornelissen

Novel clinical imaging 2

Molecular imaging using the nuclear medicine imaging techniques of single photon emission computed tomography (SPECT) and positron emission tomography (PET) allows the visualisation and quantification of biological processes in tumour tissue in living organisms. The main advantage of these non-invasive techniques is that they can be performed repeatedly in the same subject, and that the same imaging methods are used in the clinic, which makes them easier to translate from the laboratory to patients in the clinic. Because of their exceptional selectivity and sensitivity, we are mostly interested in the use of antibodies, proteins and peptides, labelled with radionuclides, to target very specific aspects of tumour biology.

Usually, molecular imaging targets are extracellular epitopes: cytokines, growth factors, or extracellular receptors. However, there is a mismatch between molecular imaging methods, which mostly target proteins or receptors on the outside of cancer cells, and cancer biology, where mostly intracellular events are studied. Therefore, one aim of the group is to develop novel methods to enable imaging of intracellular proteins, such as those involved in DNA damage repair signalling.

Furthermore, increased awareness and the rolling out of screening programmes have had a significant impact on cancer survival, especially breast cancer. The earlier a cancer is detected, the better the chances for survival are. Another aim of the group is therefore to develop methods that would allow early detection of tumour tissue.

We are evaluating the novel imaging agent developed in the group in models of breast and pancreatic cancer.

Work in the Radiopharmaceuticals and Molecular Imaging Group is funded by Cancer Research UK, EPSRC, Pancreatic Cancer Research Fund and Pancreatic Cancer UK.  

Lead Principal Investigator

Research Theme

Metabolism

Selected Publications

More publications

Latest News

Clinical researchers at Oxford University announce new collaboration with Janssen to detect blood cancers sooner

The new 7-year research collaboration with Janssen Research & Development, LLC (Janssen) will study patients at higher risk of developing certain types of blood cancers that arise from the immune system, such as chronic lymphocytic leukaemia and multiple myeloma, to identify markers that could be used to predict who will go on to develop symptomatic disease.

10-Year Partnership with Genesis Care

GenesisCare and the University of Oxford establish innovative 10-year research partnership to improve diagnosis and care for people with cancer.

Characterising an insulin-like growth factor (IGF) signature for early detection/risk reduction of cancer

Researchers in the Department of Oncology have secured funding to characterise an insulin-like growth factor (IGF) signature for early detection and risk reduction of cancer.

Oxford secures Innovate UK funding to use AI to improve diagnosis

Greg Clark, UK Secretary of State for Business, Energy and Industrial Strategy (BEIS), will confirm today (Tuesday 6 November) that UK Research and Innovation will invest £10million in the National Consortium of Intelligent Medical Imaging (NCIMI), to be led from Oxford University as part of the Industrial Strategy Challenge Fund.

Oxford collaborative science opens the way for a new drug for bowel cancer patients across the UK

Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.

Related research themes

Metabolism
Metabolism